The Cancer Letter

Inside information on cancer research and drug development

In Brief

Tom Andrus named chief digital officer at Prostate Cancer Foundation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

TOM ANDRUS was named chief digital officer and executive vice president of the Prostate Cancer Foundation.

Most recently, Andrus was general manager and senior vice president of AXS.com, a division of AEG, building a new ticketing company. Previously, he was senior vice president of product at MySpace, where he led the product, design, mobile, and search businesses.

Prior to joining MySpace, Andrus spent eight years at EarthLink where he created the company’s product management team, led business development, and established new divisions, launching the wireless, voice, cable and value-added services business units. He also led the Utilities product team at Symantec/Norton, and was one of the founding employees of Fitnesoft, a health management software company.

Table of Contents

YOU MAY BE INTERESTED IN

Black History MonthConversation with The Cancer Letter

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

By Jacquelyn Cobb
Guest Editorial

Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

By Harpreet Singh
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account